Yuko Waseda

1.4k total citations
58 papers, 937 citations indexed

About

Yuko Waseda is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Physiology. According to data from OpenAlex, Yuko Waseda has authored 58 papers receiving a total of 937 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pulmonary and Respiratory Medicine, 20 papers in Epidemiology and 14 papers in Physiology. Recurrent topics in Yuko Waseda's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (19 papers), Lung Cancer Treatments and Mutations (9 papers) and Neuroendocrine Tumor Research Advances (9 papers). Yuko Waseda is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (19 papers), Lung Cancer Treatments and Mutations (9 papers) and Neuroendocrine Tumor Research Advances (9 papers). Yuko Waseda collaborates with scholars based in Japan, Austria and Netherlands. Yuko Waseda's co-authors include Masaki Fujimura, Hazuki Takato, Kazuo Kasahara, Masahide Yasui, Satoshi Watanabe, Yukari Ichikawa, Shinji Nakao, Shoko Matsui, Takashi Sone and Hiroshi Yamamoto and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Yuko Waseda

50 papers receiving 914 citations

Peers

Yuko Waseda
Afaf Amarti Morocco
Dina El Demellawy Canada
Evangelos Bouros Greece
A. Janvresse France
R.M. duBois United Kingdom
Chang‐Bi Wang Taiwan
Susan Mathai United States
Virginia Martínez Spain
Robert A. Mickel United States
Roberto Cassandro Italy
Afaf Amarti Morocco
Yuko Waseda
Citations per year, relative to Yuko Waseda Yuko Waseda (= 1×) peers Afaf Amarti

Countries citing papers authored by Yuko Waseda

Since Specialization
Citations

This map shows the geographic impact of Yuko Waseda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuko Waseda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuko Waseda more than expected).

Fields of papers citing papers by Yuko Waseda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuko Waseda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuko Waseda. The network helps show where Yuko Waseda may publish in the future.

Co-authorship network of co-authors of Yuko Waseda

This figure shows the co-authorship network connecting the top 25 collaborators of Yuko Waseda. A scholar is included among the top collaborators of Yuko Waseda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuko Waseda. Yuko Waseda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Muto, Atsushi, Yuko Waseda, Seisuke Okazawa, et al.. (2025). Anti-MDA5 antibody-positive interstitial lung disease without prominent skin or muscle manifestations: A high-risk and potentially overlooked subgroup. Respiratory Medicine. 252. 108629–108629.
2.
Yasuoka, Hidekata, Yuko Waseda, Yuko Kaneko, et al.. (2025). Treatment patterns and clinical profile in progressive pulmonary fibrosis: a Japanese cross-sectional survey. Frontiers in Medicine. 11. 1526531–1526531.
3.
Hofman, D., et al.. (2024). Patient-centered care in pulmonary fibrosis: access, anticipate, and act. Respiratory Research. 25(1). 395–395. 2 indexed citations
4.
Isobe, Takeshi, Atsushi Miyamoto, Yuko Waseda, et al.. (2024). Nationwide Questionnaire-based Survey on Methods for Performing Bronchoalveolar Lavage. 2(3). 141–147.
5.
Handa, Tomohiro, Shoko Matsui, Hiroshi Yamamoto, et al.. (2023). The 2022 revised diagnostic criteria for IgG4-related respiratory diseases. Respiratory Investigation. 61(6). 755–759.
6.
Umeda, Yukihiro, Ryoko Egashira, Kazuhiro Tabata, et al.. (2023). Human T-cell Lymphotropic Virus Type-1-associated Bronchioloalveolar Disorder with Non-necrotizing Granulomas: A Case Report and Literature Review. Internal Medicine. 63(8). 1149–1155.
7.
8.
9.
Hisata, Shu, Masashi Bando, Sakae Homma, et al.. (2021). Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan. Respiratory Investigation. 59(6). 819–826. 17 indexed citations
10.
Waseda, Yuko, Kazunori Yamada, Kiyoaki Ito, et al.. (2021). The pronounced lung lesions developing in LATY136F knock-in mice mimic human IgG4-related lung disease. PLoS ONE. 16(3). e0247173–e0247173. 4 indexed citations
11.
Waseda, Yuko, Masahide Yasui, Toshihiro Takeda, et al.. (2021). Surfactant protein D: a useful marker for differentiation of drug-induced pneumonia and bacterial pneumonia. SHILAP Revista de lepidopterología. 13(1). 11–11. 2 indexed citations
12.
Umeda, Yukihiro, Tetsuya Tsujikawa, Masaki Anzai, et al.. (2019). The vertebral 3′-deoxy-3′-18F-fluorothymidine uptake predicts the hematological toxicity after systemic chemotherapy in patients with lung cancer. European Radiology. 29(7). 3908–3917. 5 indexed citations
13.
Kadowaki, Maiko, Hidenori Yamada, Kōichi Sato, et al.. (2019). Extracellular acidification-induced CXCL8 production through a proton-sensing receptor OGR1 in human airway smooth muscle cells: a response inhibited by dexamethasone. Journal of Inflammation. 16(1). 4–4. 15 indexed citations
14.
Watanabe, Satoshi, Kazuo Kasahara, Yuko Waseda, et al.. (2016). Imatinib ameliorates bronchiolitis obliterans via inhibition of fibrocyte migration and differentiation. The Journal of Heart and Lung Transplantation. 36(2). 138–147. 14 indexed citations
15.
Matsunuma, Ryo, Hazuki Takato, Yoshihiro Takeda, et al.. (2016). Patients with end-stage interstitial lung disease may have more problems with dyspnea than end-stage lung cancer patients. Indian Journal of Palliative Care. 22(3). 282–282. 13 indexed citations
16.
Watanabe, Satoshi, Yuko Waseda, Hazuki Takato, et al.. (2015). Pleuroparenchymal fibroelastosis: Distinct pulmonary physiological features in nine patients. Respiratory Investigation. 53(4). 149–155. 34 indexed citations
17.
Takato, Hazuki, Yuko Waseda, Satoshi Watanabe, et al.. (2012). Pulmonary manifestations of anti-ARS antibody positive interstitial pneumonia – With or without PM/DM. Respiratory Medicine. 107(1). 128–133. 35 indexed citations
18.
Waseda, Yuko, Masahide Yasui, Hazuki Takato, et al.. (2008). Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice. Respiratory Research. 9(1). 43–43. 33 indexed citations
19.
Okumura, Hirokazu, Shigeki Ohtake, Yasuo Ontachi, et al.. (2007). Living-Donor Lobar Lung Transplantation for Broncho-Bronchiolitis Obliterans after Allogeneic Hematopoietic Stem Cell Transplantation: Does Bronchiolitis Obliterans Recur in Transplanted Lungs?. International Journal of Hematology. 86(4). 369–373. 13 indexed citations
20.
Kimura, Hideharu, Kazuo Kasahara, Kazuhiko Shibata, et al.. (2006). EGFR Mutation of Tumor and Serum in Gefitinib-Treated Patients with Chemotherapy-Naive Non–small Cell Lung Cancer. Journal of Thoracic Oncology. 1(3). 260–267. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Afaf Amarti Breakdown of academic impact, for papers by Dina El Demellawy Breakdown of academic impact, for papers by Evangelos Bouros Breakdown of academic impact, for papers by A. Janvresse Breakdown of academic impact, for papers by R.M. duBois Breakdown of academic impact, for papers by Chang‐Bi Wang Breakdown of academic impact, for papers by Susan Mathai Breakdown of academic impact, for papers by Virginia Martínez Breakdown of academic impact, for papers by Robert A. Mickel Breakdown of academic impact, for papers by Roberto Cassandro
Rankless by CCL
2026